Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3297468rdf:typepubmed:Citationlld:pubmed
pubmed-article:3297468lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:3297468lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:3297468lifeskim:mentionsumls-concept:C0020223lld:lifeskim
pubmed-article:3297468lifeskim:mentionsumls-concept:C0071074lld:lifeskim
pubmed-article:3297468lifeskim:mentionsumls-concept:C0085580lld:lifeskim
pubmed-article:3297468lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:3297468pubmed:issue1lld:pubmed
pubmed-article:3297468pubmed:dateCreated1987-8-12lld:pubmed
pubmed-article:3297468pubmed:abstractTextPinacidil is a direct vasodilator with good absorption, a half-life of 2 to 4 hours, and side effects similar to those of other vasodilators. We hypothesized that controlled-release pinacidil would be comparable to or better than hydralazine for blood pressure control and side effects. A double-blind, randomized trial comparing pinacidil with hydralazine when combined with hydrochlorothiazide or propranolol to control side effects or the diastolic blood pressure was performed. Pinacidil decreased systolic and diastolic blood pressure from 156/100 mm Hg to 132/81 mm Hg. The increase in heart rate and weight with both drugs was controlled with the additional drugs. There was 1/17 successes on monotherapy with both drugs. When combined with other drugs there were 15/18 successes with hydralazine and 16/20 successes with pinacidil. Side effects were typical of vasodilators. Both drugs acutely increased plasma norepinephrine and epinephrine during chronic therapy.lld:pubmed
pubmed-article:3297468pubmed:languageenglld:pubmed
pubmed-article:3297468pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3297468pubmed:statusMEDLINElld:pubmed
pubmed-article:3297468pubmed:monthJullld:pubmed
pubmed-article:3297468pubmed:issn0009-9236lld:pubmed
pubmed-article:3297468pubmed:authorpubmed-author:NiesA SASlld:pubmed
pubmed-article:3297468pubmed:authorpubmed-author:ByynyR LRLlld:pubmed
pubmed-article:3297468pubmed:authorpubmed-author:MitchellW DWDlld:pubmed
pubmed-article:3297468pubmed:authorpubmed-author:LoVerdeM EMElld:pubmed
pubmed-article:3297468pubmed:issnTypePrintlld:pubmed
pubmed-article:3297468pubmed:volume42lld:pubmed
pubmed-article:3297468pubmed:ownerNLMlld:pubmed
pubmed-article:3297468pubmed:authorsCompleteYlld:pubmed
pubmed-article:3297468pubmed:pagination50-7lld:pubmed
pubmed-article:3297468pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:meshHeadingpubmed-meshheading:3297468-...lld:pubmed
pubmed-article:3297468pubmed:year1987lld:pubmed
pubmed-article:3297468pubmed:articleTitleA double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.lld:pubmed
pubmed-article:3297468pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3297468pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3297468pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3297468pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:3297468pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed